PBPK model predicts modestly lower acetaminophen exposure in pregnancy
This computational pharmacokinetic analysis quantifies how pregnancy alters acetaminophen disposition and estimates theoretical dose adjustments, offering Women's Health pharmacists mechanistic context for a drug used by roughly 40% of pregnant patients.
📅 Journal publication: Dec 1, 2026·Last updated: Oct 13, 2026
acetaminophenparacetamolPBPK modelingpregnancypharmacokineticsWomen's HealthdosingsulfotransferaseglucuronidationNAPQIin silico studyWomen's Health / Reproductive
Understanding acetaminophen (APAP) pharmacokinetics during pregnancy ensures safe and effective dosing for pregnant women. The clearance rate and half-life of intravenous APAP increased throughout pregnancy, suggesting dose adjustments are needed, especially in the third trimester. The study highlights the need for adjusted dosing of APAP in pregnant women to achieve therapeutic effects, particularly in later pregnancy stages. Pregnancy significantly alters APAP pharmacokinetics; dose adjustments are essential, especially in the third trimester.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Kong W, Yang Y, Guan X, et al. PBPK modeling of intravenous/oral acetaminophen in healthy and pregnant individuals. Pakistan journal of pharmaceutical sciences. 2026;39(12):3706-3716. doi:10.36721/PJPS.2026.39.12.340.1
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.